These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26842686)

  • 61. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
    Leuthner KD; Yuen A; Mao Y; Rahbar A
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
    Sincak CA; Schmidt JM
    Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Glycopeptide antibiotics: back to the future.
    Butler MS; Hansford KA; Blaskovich MA; Halai R; Cooper MA
    J Antibiot (Tokyo); 2014 Sep; 67(9):631-44. PubMed ID: 25118105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
    Cardona AF; Wilson SE
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
    Roecker AM; Pope SD
    Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Coyle EA; Rybak MJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):706-9. PubMed ID: 11181347
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
    Mendes RE; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.
    Rubino CM; Bhavnani SM; Moeck G; Bellibas SE; Ambrose PG
    Antimicrob Agents Chemother; 2015; 59(6):3365-72. PubMed ID: 25824211
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
    Schirmer PL; Deresinski SC
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
    Bhavnani SM; Owen JS; Loutit JS; Porter SB; Ambrose PG
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):95-102. PubMed ID: 15474317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
    Arhin FF; Belley A; McKay GA; Moeck G
    Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
    Chastain DB; Davis A
    Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.